These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36815647)

  • 1. Nanomaterials as a Potential Target for Infectious Parasitic Agents.
    Alsharedeh RH; Rezigue M; Bashatwah RM; Amawi H; Aljabali AAA; Obeid MA; Tambuwala MM
    Curr Drug Deliv; 2024; 21(6):828-851. PubMed ID: 36815647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs.
    Kayser O; Olbrich C; Croft SL; Kiderlen AF
    Parasitol Res; 2003 Jun; 90 Suppl 2():S63-70. PubMed ID: 12937968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles.
    Date AA; Joshi MD; Patravale VB
    Adv Drug Deliv Rev; 2007 Jul; 59(6):505-21. PubMed ID: 17574295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parasitic infections and myositis.
    El-Beshbishi SN; Ahmed NN; Mostafa SH; El-Ganainy GA
    Parasitol Res; 2012 Jan; 110(1):1-18. PubMed ID: 21881948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles for antiparasitic drug delivery.
    Sun Y; Chen D; Pan Y; Qu W; Hao H; Wang X; Liu Z; Xie S
    Drug Deliv; 2019 Dec; 26(1):1206-1221. PubMed ID: 31746243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium Metallotherapeutics: Novel Approaches to Combatting Parasitic Infections.
    Britten NS; Butler JA
    Curr Med Chem; 2022 Aug; 29(31):5159-5178. PubMed ID: 35366762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transporters for drug delivery and as drug targets in parasitic protozoa.
    Landfear SM
    Clin Pharmacol Ther; 2010 Jan; 87(1):122-5. PubMed ID: 19571801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria as a promising antiparasitic target.
    Monzote L; Gille L
    Curr Clin Pharmacol; 2010 Feb; 5(1):55-60. PubMed ID: 20236083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted drug delivery to macrophages in parasitic infections.
    Owais M; Gupta CM
    Curr Drug Deliv; 2005 Oct; 2(4):311-8. PubMed ID: 16305434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets.
    Liotta F; Siekierka JJ
    Curr Opin Investig Drugs; 2010 Feb; 11(2):147-56. PubMed ID: 20112164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential chemotherapeutic targets in the purine metabolism of parasites.
    el Kouni MH
    Pharmacol Ther; 2003 Sep; 99(3):283-309. PubMed ID: 12951162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology: A promising strategy for the control of parasitic infections.
    AlGabbani Q
    Exp Parasitol; 2023 Jul; 250():108548. PubMed ID: 37196702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From chemical graphs in computer-aided drug design to general Markov-Galvez indices of drug-target, proteome, drug-parasitic disease, technological, and social-legal networks.
    Riera-Fernández P; Munteanu CR; Dorado J; Martin-Romalde R; Duardo-Sanchez A; González-Diaz H
    Curr Comput Aided Drug Des; 2011 Dec; 7(4):315-37. PubMed ID: 22050683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era.
    Huh AJ; Kwon YJ
    J Control Release; 2011 Dec; 156(2):128-45. PubMed ID: 21763369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses.
    Serban G
    Acta Pharm; 2020 Sep; 70(3):259-290. PubMed ID: 32074064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues.
    González-Díaz H; Romaris F; Duardo-Sanchez A; Pérez-Montoto LG; Prado-Prado F; Patlewicz G; Ubeira FM
    Curr Pharm Des; 2010; 16(24):2737-64. PubMed ID: 20642428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting histone acetylation/deacetylation in parasites: an update (2017-2020).
    Fioravanti R; Mautone N; Rovere A; Rotili D; Mai A
    Curr Opin Chem Biol; 2020 Aug; 57():65-74. PubMed ID: 32615359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to antiparasitic drugs: the role of molecular diagnosis.
    Sangster N; Batterham P; Chapman HD; Duraisingh M; Le Jambre L; Shirley M; Upcroft J; Upcroft P
    Int J Parasitol; 2002 May; 32(5):637-53. PubMed ID: 11943235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery strategies for antiparasitics.
    Kayser O; Kiderlen AF
    Expert Opin Investig Drugs; 2003 Feb; 12(2):197-207. PubMed ID: 12556214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Inhibitors as Antiparasitic Drugs: Pharmacological, Biochemical and Molecular Perspectives.
    Mukherjee S; Mukherjee N; Gayen P; Roy P; Babu SP
    Curr Drug Metab; 2016; 17(10):937-970. PubMed ID: 27719626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.